… Inhibitors of the EGFR have emerged as promising anticancer agents and two main … tyrosine
kinase inhibitors. This review discusses the current status of EGFR tyrosine kinase inhibitors …

… growth factor (VEGF) receptor tyrosine kinase inhibitors. Sorafenib (BAY 43-9006) additionally
inhibits the Raf kinase … are dual inhibitors of both the epidermal growth factor receptor (…

… first inhibitor of tyrosine kinase activity to be described was quercetin, which is able to block
several tyrosine kinases … Quercetin was also the first tyrosine kinase inhibitor (TKI) tested in a …

… kinases define a clinically validated class of targets for cancer drug therapy 1 . However, the
efficacy of kinase inhibitors in … to those transduced by the targeted kinase 4 . Cancer cells …

… Schematic of the kinase domain of epidermal growth factor receptor showing exons 18 to
21. Activating drug-sensitive mutations are shown on the top, and tyrosine kinase inhibitor (TKI) …

… Here, we describe the status of small-molecule EGFR tyrosine kinase inhibitors in … specific
kinase inhibitors [4]. Of note, Gilmore et al. recently demonstrated that insulin-like growth factor …

… Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) …
resistance through overexpression of the hepatocyte growth factor and suppression of Bcl-2-like …

… growth factor (EGF) receptor tyrosine kinase and, to a lesser … inhibits EGF-dependent
EGF receptor phosphorylation … growth factor- or platelet-derived growth factor-induced …

… various autocrine and paracrine growth factors including TGF-α… on the production of these
growth factors in vivo. Therefore, … kinase inhibitors targeted to the epidermal growth factor …

… kinase inhibitor compounds with sufficient potency, bioavailability and selectivity against this
subfamily of receptor tyrosine kinases. … is the first of these inhibitor compounds to gain FDA …